Reports Q1 revenue $801.4M, consensus $772.47M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “Bruker had a solid start to 2025 with double-digit reported and CER revenue growth, 5.1% organic revenue growth in our BSI segment, and better operating margin performance than expected – all on strong execution, despite uncertainties in key markets. In Q1 and April, we launched key products in spatial biology, NMR, microbiology and molecular diagnostics. Proactive cost management helped drive organic operating margin expansion, partially offsetting the expected Q1 margin headwinds from our strategic acquisitions in Q2 of 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- BRKR Earnings this Week: How Will it Perform?
- Bruker downgraded to Neutral from Buy at Cleveland Research
- Bruker annouces majority investment in RECIPE Chemicals + Instruments
- Bruker Corporation: Strategic Positioning and Growth Prospects Drive Buy Rating
- China raises tariffs on U.S. goods, banks report Q1 results: Morning Buzz